Literature DB >> 34160593

ECCO Topical Review: Refractory Inflammatory Bowel Disease.

Tim Raine1, Bram Verstockt2,3, Uri Kopylov4,5, Konstantinos Karmiris6, Rimma Goldberg7, Raja Atreya8, Johan Burisch9, John Burke10, Pierre Ellul11, Charlotte Hedin12,13, Stefan D Holubar14, Konstantinos Katsanos15, Triana Lobaton16, Carsten Schmidt17, Garret Cullen18.   

Abstract

Inflammatory bowel disease is a chronic disease with variable degrees of extent, severity, and activity. A proportion of patients will have disease that is refractory to licensed therapies, resulting in significant impairment in quality of life. The treatment of these patients involves a systematic approach by the entire multidisciplinary team, with particular consideration given to medical options including unlicensed therapies, surgical interventions, and dietetic and psychological support. The purpose of this review is to guide clinicians through this process and provide an accurate summary of the available evidence for different strategies.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; refractory; ulcerative colitis; unlicensed medication

Mesh:

Substances:

Year:  2021        PMID: 34160593     DOI: 10.1093/ecco-jcc/jjab112

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   10.020


  4 in total

Review 1.  [Living guideline on ulcerative colitis].

Authors:  Torsten Kucharzik
Journal:  Chirurg       Date:  2022-02-15       Impact factor: 0.955

Review 2.  Stem cell transplantation for induction of remission in medically refractory Crohn's disease.

Authors:  Sarah El-Nakeep; Ahmed Shawky; Sara F Abbas; Osama Abdel Latif
Journal:  Cochrane Database Syst Rev       Date:  2022-05-13

Review 3.  When disease extent is not always a key parameter: Management of refractory ulcerative proctitis.

Authors:  Georgios Michalopoulos; Konstantinos Karmiris
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-12-11

Review 4.  The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era.

Authors:  Gerasimos Evangelatos; Giorgos Bamias; George D Kitas; George Kollias; Petros P Sfikakis
Journal:  Rheumatol Int       Date:  2022-05-03       Impact factor: 3.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.